Hybrid imaging with positron emission tomography and computed tomography (PET/CT) in the pituitary region of the brain is a promising tool for differentiating military veterans with post-traumatic stress disorder (PTSD) from those with mild traumatic brain injury (MTBI), according to a new study presented at the annual meeting of the Radiological Society of North America (RSNA).
The findings also lend support to the theory that many veterans diagnosed with PTSD may actually have hormonal irregularities due to pituitary gland damage from blast injury.
MTBI involves damage to the brain from an external force, while PTSD is generally defined as a mental health condition that can develop after someone has experienced a traumatic event. Research has shown that up to 44 percent of returning veterans with MTBI and loss of consciousness also meet the criteria for PTSD. Differentiating PTSD from MTBI can be challenging for clinicians due to symptom overlap and, in many cases, normal structural neuroimaging results.
Researchers recently used PET/CT to study the hypothalamus and pituitary glands of veterans who had suffered blast-related MTBI. The pituitary gland is a pea-sized structure that sits in the bony enclosure located at the base of the skull and is connected to a part of the brain called the hypothalamus. Together with the adrenal glands above each kidney, the hypothalamus and pituitary gland form the HPA axis, an important regulator of many body processes, including stress response, mood and energy expenditure.
The HPA axis is a complex system with a feedback loop, so that damage to any one of the three areas will affect the others. It’s suspected of playing an important role in PTSD, but there is limited neuroimaging research in the veteran population.
The researchers focused on 18F-fluorodeoxyglucose (18F-FDG) PET/CT, which provides a picture of metabolism by measuring uptake of the radiopharmaceutical FDG. A review of 159 brain 18F-FDG PET/CT exam records showed that FDG uptake in the hypothalamus was significantly lower in the MTBI-only group compared with normal controls. FDG uptake in the pituitary gland was significantly higher in the MTBI and PTSD group compared with the MTBI-only group.
The finding of higher FDG uptake in the pituitary glands of PTSD sufferers supports the theory that many veterans diagnosed with PTSD may actually have hypopituitarism, a condition in which the pituitary gland does not produce normal amounts of one or more of its hormones.
The team state that this raises the possibility that some PTSD cases are actually hypopituitarism masking itself as PTSD. If that’s the case, then we might be able to help those patients by screening for hormone irregularities and treating those irregularities on an individual basis. The increased FDG uptake in the pituitary glands of veterans with MTBI and PTSD may be due to the gland working harder to produce hormones.
The results suggest that PET/CT may provide an effective way to diagnose and differentiate PTSD from MTBI and offer more insight into the biological manifestations of the disorder.
The team summise that the study sheds light on the complex issue of PTSD, which also has symptom overlap with depression and anxiety. Currently, treatment for PTSD is typically limited to psychological therapy, antidepressants and anxiety medications. The findings reinforce the theory that there is something physically and biologically different in veterans who have MTBI and PTSD compared to those who just have MTBI and available therapies must be evolved to deal with this breakthrough.